

# Stavros Gravas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1343696/publications.pdf>

Version: 2024-02-01

83  
papers

3,475  
citations

361413

20  
h-index

144013

57  
g-index

86  
all docs

86  
docs citations

86  
times ranked

3597  
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. <i>European Urology</i> , 2013, 64, 118-140.	1.9	990
2	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. <i>European Urology</i> , 2015, 67, 1099-1109.	1.9	735
3	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020, 78, 21-28.	1.9	239
4	Critical review of lasers in benign prostatic hyperplasia (BPH). <i>BJU International</i> , 2011, 107, 1030-1043.	2.5	137
5	Laser Treatment of Benign Prostatic Obstruction: Basics and Physical Differences. <i>European Urology</i> , 2012, 61, 317-325.	1.9	123
6	Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 70, 788-796.	1.9	84
7	Current status of 5 $\alpha$ -reductase inhibitors in the management of lower urinary tract symptoms and BPH. <i>World Journal of Urology</i> , 2010, 28, 9-15.	2.2	77
8	Feasibility of Percutaneous Nephrolithotomy under Assisted Local Anaesthesia: A Prospective Study on Selected Patients with Upper Urinary Tract Obstruction. <i>European Urology</i> , 2007, 51, 224-228.	1.9	65
9	A Systematic Review of Patients' Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms. <i>European Urology</i> , 2021, 79, 796-809.	1.9	65
10	Systematic Review of the Performance of Noninvasive Tests in Diagnosing Bladder Outlet Obstruction in Men with Lower Urinary Tract Symptoms. <i>European Urology</i> , 2017, 71, 391-402.	1.9	64
11	Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. <i>European Urology</i> , 2017, 72, 757-769.	1.9	59
12	Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 75, 788-798.	1.9	46
13	Transurethral Microwave Thermotherapy: The Gold Standard for Minimally Invasive Therapies for Patients with Benign Prostatic Hyperplasia?. <i>Journal of Endourology</i> , 2003, 17, 245-251.	2.1	44
14	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICIERS 2015). <i>Neurourology and Urodynamics</i> , 2017, 36, 882-893.	1.5	44
15	Safety and tolerability of $\beta_3$ -adrenoceptor agonists in the treatment of overactive bladder syndrome – insight from transcriptome and experimental studies. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 647-657.	2.4	42
16	Forgotten, Encrusted Ureteral Stents: A Challenging Problem with an Endourologic Solution. <i>Journal of Endourology</i> , 2006, 20, 1045-1049.	2.1	41
17	European Association of Urology Guidelines on Male Urinary Incontinence. <i>European Urology</i> , 2022, 82, 387-398.	1.9	37
18	What Is the Required Certainty of Evidence for the Implementation of Novel Techniques for the Treatment of Benign Prostatic Obstruction?. <i>European Urology Focus</i> , 2019, 5, 351-356.	3.1	34

#	ARTICLE	IF	CITATIONS
19	Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. <i>Therapeutic Advances in Urology</i> , 2018, 10, 79-92.	2.0	31
20	The effect of hexanic extract of <i>Serenoa repens</i> on prostatic inflammation: results from a randomized biopsy study. <i>World Journal of Urology</i> , 2019, 37, 539-544.	2.2	28
21	Lasers in Transurethral Enucleation of the Prostate—Do We Really Need Them. <i>Journal of Clinical Medicine</i> , 2020, 9, 1412.	2.4	23
22	Impact of COVID-19 on medical education: introducing homo digitalis. <i>World Journal of Urology</i> , 2021, 39, 1997-2003.	2.2	22
23	Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. <i>BMC Urology</i> , 2015, 15, 65.	1.4	20
24	Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. <i>European Urology Focus</i> , 2020, 6, 1104-1110.	3.1	20
25	Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. <i>European Urology</i> , 2021, 79, 492-504.	1.9	20
26	Durability of 30-Minute High-Energy Transurethral Microwave Therapy for Treatment of Benign Prostatic Hyperplasia: A Study of 213 Patients With and Without Urinary Retention. <i>Urology</i> , 2007, 69, 854-858.	1.0	19
27	The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery. <i>Current Urology Reports</i> , 2016, 17, 61.	2.2	18
28	Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG. <i>Tumor Biology</i> , 2014, 35, 4185-4189.	1.8	17
29	Impact of COVID-19 on Urology Practice: A Global Perspective and Snapshot Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1730.	2.4	16
30	Advances in Ultrasound Technology in Oncologic Urology. <i>Urologic Clinics of North America</i> , 2009, 36, 133-145.	1.8	15
31	Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?. <i>Current Opinion in Urology</i> , 2009, 19, 49-54.	1.8	15
32	Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721982897.	2.0	15
33	Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinat hydrochloride?. <i>Canadian Journal of Urology</i> , 2012, 19, 6269-73.	0.0	14
34	SEEKING EVIDENCE THAT CELL KILL GUIDED THERMOTHERAPY GIVES RESULTS NOT INFERIOR TO THOSE OF TRANSURETHRAL PROSTATE RESECTION: RESULTS OF A POOLED ANALYSIS OF 3 STUDIES OF FEEDBACK TRANSURETHRAL MICROWAVE THERMOTHERAPY. <i>Journal of Urology</i> , 2005, 174, 1002-1006.	0.4	13
35	Tolterodine extended release in the treatment of male oab/storage luts: a systematic review. <i>BMC Urology</i> , 2014, 14, 84.	1.4	13
36	Quality of Life and Sexual Health in the Aging of PCa Survivors. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-16.	1.5	13

#	ARTICLE	IF	CITATIONS
37	A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance. <i>World Journal of Urology</i> , 2016, 34, 1555-1559.	2.2	12
38	Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2016, 8, 19-28.	2.0	12
39	Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. <i>Journal of Clinical Medicine</i> , 2019, 8, 1126.	2.4	12
40	Endobronchial metastasis from prostate cancer. <i>International Urology and Nephrology</i> , 2008, 40, 961-964.	1.4	10
41	Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in&nbsp;patients with benign prostatic hyperplasia. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1707.	4.3	10
42	Mobile Health in Urology: The Good, the Bad and the Ugly. <i>Journal of Clinical Medicine</i> , 2020, 9, 1016.	2.4	10
43	Translation of benign prostatic hyperplasia guidelines into clinical practice. <i>Current Opinion in Urology</i> , 2008, 18, 56-60.	1.8	9
44	Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia. <i>European Urology Supplements</i> , 2009, 8, 513-522.	0.1	9
45	Tolterodine in the Treatment of Male LUTS. <i>Current Urology Reports</i> , 2015, 16, 60.	2.2	9
46	Do $\beta_3$ -adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F859-F861.	2.7	9
47	Extracorporeal shock-wave lithotripsy and garlic consumption: a lesson to learn. <i>Urological Research</i> , 2010, 38, 61-63.	1.5	8
48	New therapeutic strategies for the treatment of male lower urinary tract symptoms. <i>Research and Reports in Urology</i> , 2016, 8, 51.	1.0	8
49	Lower Urinary Tract Symptoms Including Bladder Outlet Obstruction: What's New in Diagnostics?. <i>European Urology Focus</i> , 2018, 4, 14-16.	3.1	8
50	Minimally Invasive Treatment of Male Lower Urinary Tract Symptoms. <i>Urologic Clinics of North America</i> , 2008, 35, 505-518.	1.8	7
51	Desensitization of cAMP Accumulation via Human $\beta_3$ -Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. <i>Frontiers in Pharmacology</i> , 2019, 10, 596.	3.5	7
52	Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NF $\kappa$ B Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression. <i>Pathology and Oncology Research</i> , 2019, 25, 225-231.	1.9	7
53	Hot Topics in the Clinical Practice Guidelines for Treatment of Male Lower Urinary Tract Symptoms due to Benign Prostatic Obstruction. <i>European Urology Focus</i> , 2022, 8, 396-398.	3.1	6
54	Feasibility and safety of radical cystectomy under combined spinal and epidural anesthesia in octogenarian patients with ASA score $\geq 3$ : A case series. <i>Canadian Urological Association Journal</i> , 2015, 9, 500.	0.6	5

#	ARTICLE	IF	CITATIONS
55	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. <i>European Urology Focus</i> , 2021, 7, 432-439.	3.1	5
56	Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society. <i>World Journal of Urology</i> , 2010, 28, 1-2.	2.2	4
57	Is Focal Therapy an Alternative to Active Surveillance?. <i>Journal of Endourology</i> , 2010, 24, 855-860.	2.1	4
58	Focal therapy for prostate cancer: patient selection and evaluation. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 77-86.	2.4	4
59	Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle-invasive bladder cancer. <i>Tumor Biology</i> , 2015, 36, 4699-4705.	1.8	4
60	Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18-months results. <i>World Journal of Urology</i> , 2022, 40, 727-738.	2.2	4
61	Juvenile Granulosa Cell Tumor of the Epididymis. <i>Urologia Internationalis</i> , 2007, 78, 278-279.	1.3	3
62	Transurethral microwave thermotherapy: from evidence-based medicine to clinical practice. <i>Current Opinion in Urology</i> , 2007, 17, 12-16.	1.8	3
63	Cross-continental comparison of safety and protection measures amongst urologists during COVID-19. <i>International Journal of Urology</i> , 2020, 27, 981-989.	1.0	3
64	Preservation of antegrade ejaculation after surgical relief of benign prostatic obstruction is a valid endpoint. <i>World Journal of Urology</i> , 2021, 39, 2277-2289.	2.2	3
65	The use of an artificial neural network in the evaluation of the extracorporeal shockwave lithotripsy as a treatment of choice for urinary lithiasis. <i>Asian Journal of Urology</i> , 2022, 9, 132-138.	1.2	3
66	Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	2.5	3
67	Comment on: Management of forgotten ureteral stents with holmium laser. <i>Lasers in Medical Science</i> , 2009, 24, 293-294.	2.1	2
68	Prostate Volume as a Risk Factor for Lower Urinary Tract Symptoms: The Quest Continues. <i>European Urology</i> , 2016, 69, 892-893.	1.9	2
69	The Relationship Between Inflammation and LUTS/BPH. , 2018, , 31-50.		2
70	The Clinical Impact of Hexanic Extract of <i>Serenoa repens</i> in Men with Prostatic Inflammation: A Post Hoc Analysis of a Randomized Biopsy Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 957.	2.4	2
71	Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 143-147.	0.8	2
72	Epidemiologic trends indicate the prevalence of obesity will rise globally. <i>European Urology</i> , 2007, 52, 204-5.	1.9	2

#	ARTICLE	IF	CITATIONS
73	TURPxit or not: the guidelines perspectiveâ€”Panta Rhei. World Journal of Urology, 2021, 39, 2399-2400.	2.2	1
74	Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luoâ€™s Letter to the Editor re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschiepfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492â€”504. European Urology, 2021, 79, e147-e148.	1.9	1
75	Outcomes of combination therapy with daily Tadalafil 5mg plus Tamsulosin 0.4mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. Minerva Urology and Nephrology, 2020, , .	2.5	1
76	Editorial Comment on: Update on Training Models in Endourology: A Qualitative Systematic Review of the Literature between January 1980 and April 2008. European Urology, 2008, 54, 1260-1261.	1.9	0
77	Editorial Comment on: Chronic Pelvic Pain and Lower Urinary Tract Symptoms in Both Sexes: Analysis of 2749 Participants of an Urban Health Screening Project. European Urology, 2009, 55, 508.	1.9	0
78	Re: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. European Urology, 2015, 68, 338-339.	1.9	0
79	Generalized Lymphadenopathy of Prostate Adenocarcinoma Origin. A Case Series. Urology, 2016, 91, e3-e4.	1.0	0
80	Reply to Jae Hung Jung, Julia L. Han, and Philipp Dahm's Letter to the Editor re: Vasileios I. Sakalis, Markos Karavitakis, Dina Bedretdinova, et al. Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. Eur Urol 2017;72:757â€”69. European Urology, 2018, 73, e60-e62.	1.9	0
81	Practice Patterns in Diagnosis and Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia among General Practitioners: Lessons Learnt from a Greek Survey. Balkan Medical Journal, 2018, 35, 287-288.	0.8	0
82	Mind the gap: management of benign prostatic obstruction (BPO) surgical candidates on antithrombotics. World Journal of Urology, 2020, 38, 247-248.	2.2	0
83	Translation and validation of the Italian version of the user version of the Mobile Application Rating Scale (uMARS). Journal of Preventive Medicine and Hygiene, 2021, 62, E243-E248.	0.9	0